In conclusion, our study revealed the mechanism of ID1 mediated resistance to osimertinib in EGFR T790M-positive NSCLC through EMT, which may provide new ideas and methods for the clinical treatment of EGFR mutated NSCLC after osimertinib resistance. Here, ID1 is linked to non-small cell lung carcinoma.